{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:03:51Z","timestamp":1782126231369,"version":"3.54.5"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:sec><jats:title\/><jats:p>Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression. However, emerging reports have indicated various adverse drug reactions with the use of lurasidone. Thus, in this article, we have analyzed the risk profile of lurasidone in the established therapeutic indication. A total of 419 studies were published from October 2010-July 2019 regarding lurasidone. After the inclusion and exclusion criteria, 17 studies were selected for the analysis of risk. The adverse drug reactions (ADRs) of these studies were categorized as per the innovator summary of product characteristics (SmPC). Finally, the unlisted ADRs were analyzed by using the Naranjo probability algorithm. Telogen effluvium, thrombocytopenia, restless leg syndrome and hypersexuality were found with the use of lurasidone and fall under the unlisted category. The causality assessment has shown a probable correlation of lurasidone with hypersexuality, restless leg syndrome, thrombocytopenia and possible relation with telogen effluvium. In conclusion, lurasidone is a novel and efficacious pharmacological treatment for bipolar depression and schizophrenia. However, more data regarding the safety of this drug in a large population is needed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871527319666200303120147","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:25:50Z","timestamp":1583241950000},"page":"109-114","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression"],"prefix":"10.2174","volume":"19","author":[{"given":"Harika","family":"Modugula","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Lucknow (UP) -226002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Lucknow (UP) -226002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1871527317666171213162403","volume":"16","author":"de Souza T.B.","year":"2018","unstructured":"de Souza T.B.; Farias D.M.; Coletti R.F.; Oliveira M.S.; Carrilho C.G.; de Barros J.A.; Moreno S.E.; Murillo-Rodriguez E.; Machado S.; Veras A.B.; Systemic administration of antipsychotic asenapine pre or postnatal does not induce anxiety-like behaviors in mice. CNS Neurol Disord Drug Targets 2018,16(10),1127-1133","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1871527317666181119115532","volume":"18","author":"Sirivichayakul S.","year":"2019","unstructured":"Sirivichayakul S.; Kanchanatawan B.; Thika S.; Carvalho A.F.; Maes M.; A New schizophrenia model: immune activation is associated with the induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions. CNS Neurol Disord Drug Targets 2019,18(2),124-140","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/1871527317666180605120244","volume":"17","author":"Gerasimou C.","year":"2018","unstructured":"Gerasimou C.; Tsoporis J.N.; Siafakas N.; Hatziagelaki E.; Kallergi M.; Chatziioannou S.N.; Parker T.G.; Parissis J.; Salpeas V.; Papageorgiou C.; Rizos E.; A Longitudinal study of alterations of S100B, sRAGE and fas ligand in association to olanzapine medication in a sample of first episode patients with schizophrenia. CNS Neurol Disord Drug Targets 2018,17(5),383-388","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/1871527317666180702160921","volume":"17","author":"Kanchanatawan B.","year":"2018","unstructured":"Kanchanatawan B.; Maes M.; The Effects of tryptophan catabolites on negative symptoms and deficit schizophrenia are partly mediated by executive impairments: results of partial least squares path modeling. CNS Neurol Disord Drug Targets 2018,17(6),473-486","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/yd.23320019106","volume":"91","author":"Dincin J.","year":"2001","unstructured":"Dincin J.; The biological basis of mental illness. New Dir Ment Health Serv Fall 2001,91,47-56","journal-title":"New Dir Ment Health Serv Fall"},{"key":"ref=6","year":"2002","unstructured":"Mental Health: New Understanding World Health Organization2002","journal-title":"Mental Health: New Understanding"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2174\/1871527317666180412153612","volume":"17","author":"Healy-Stoffel M.","year":"2018","unstructured":"Healy-Stoffel M.; Levant B.; N-3 (Omega-3) fatty acids: effects on brain dopamine systems and potential role in the etiology and treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2018,17(3),216-232","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=8","year":"2013","unstructured":"Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association2013","journal-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1177\/070674379704200121","volume":"42","author":"Yatham L.N.","year":"1997","unstructured":"Yatham L.N.; Kusumakar V.; Parikh S.V.; Haslam D.R.; Matte R.; Sharma V.; Kennedy S.; Bipolar depression: treatment options. Can J Psychiatry 1997,42(2)(Suppl. 2),87S-91S","journal-title":"Can J Psychiatry"},{"key":"ref=10","first-page":"1521","volume":"9","author":"Woo Y.S.","year":"2013","unstructured":"Woo Y.S.; Wang H.R.; Bahk W.M.; Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 2013,9,1521-1529","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1176\/appi.ajp.2013.13091240","volume":"171","author":"Belmaker R.H.","year":"2014","unstructured":"Belmaker R.H.; Lurasidone and bipolar disorder. Am J Psychiatry 2014,171(2),131-133","journal-title":"Am J Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"B40","DOI":"10.1016\/j.clinthera.2011.11.020","volume":"33","author":"Srivastava S.","year":"2011","unstructured":"Srivastava S.; Ketter T.A.; Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther 2011,33(12),B40-B48","journal-title":"Clin Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/1871527317666180828120256","volume":"17","author":"Mazza M.","year":"2018","unstructured":"Mazza M.; Marano G.; Traversi G.; Carocci V.; Romano B.; Janiri L.; Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets 2018,17(10),723-727","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=14","first-page":"1","volume":"26","author":"Sagman D.","year":"2009","unstructured":"Sagman D.; Tohen M.; Comorbidity in bipolar disorder. Psychiatr Times 2009,26(4),1-9","journal-title":"Psychiatr Times"},{"key":"ref=15","first-page":"21","volume":"12","author":"Bawa R.","year":"2015","unstructured":"Bawa R.; Scarff J.R.; Lurasidone: a new treatment option for bipolar depression-a review. Innov Clin Neurosci 2015,12(1-2),21-23","journal-title":"Innov Clin Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","volume":"171","author":"Loebel A.","year":"2014","unstructured":"Loebel A.; Cucchiaro J.; Silva R.; Kroger H.; Sarma K.; Xu J.; Calabrese J.R.; Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014,171(2),169-177","journal-title":"Am J Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1517\/14656566.2015.1058780","volume":"16","author":"Bruijnzeel D.","year":"2015","unstructured":"Bruijnzeel D.; Yazdanpanah M.; Suryadevara U.; Tandon R.; Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opin Pharmacother 2015,16(10),1559-1565","journal-title":"Expert Opin Pharmacother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"Ogasa M.","year":"2013","unstructured":"Ogasa M.; Kimura T.; Nakamura M.; Guarino J.; Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013,225(3),519-530","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"Loebel A.","year":"2014","unstructured":"Loebel A.; Cucchiaro J.; Silva R.; Kroger H.; Hsu J.; Sarma K.; Sachs G.; Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014,171(2),160-168","journal-title":"Am J Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D.","year":"2009","unstructured":"Moher D.; Liberati A.; Tetzlaff J.; Altman D.G.; Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med PRISMA Group2009,6(7)","journal-title":"PLoS Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"Downs S.H.","year":"1998","unstructured":"Downs S.H.; Black N.; The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998,52(6),377-384","journal-title":"J Epidemiol Community Health"},{"key":"ref=22","unstructured":"SmPC of lurasidone from electronic medical compendium. Available at Accessed on July 20th 2019."},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JCP.0000000000000934","volume":"38","author":"Reddy B.","year":"2018","unstructured":"Reddy B.; Das S.; Ali M.; A Case of hypersexuality probably associated with lurasidone. J Clin Psychopharmacol 2018,38(5),537-539","journal-title":"J Clin Psychopharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/JCP.0000000000000496","volume":"36","author":"Ghori A.K.","year":"2016","unstructured":"Ghori A.K.; Sajatovic M.; Tampi R.R.; A Case of emergent restless legs syndrome with lurasidone therapy. J Clin Psychopharmacol 2016,36(3),293-294","journal-title":"J Clin Psychopharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/IJPSYM.IJPSYM_374_17","volume":"40","author":"Rafi M.","year":"2018","unstructured":"Rafi M.; Goyal C.; Reddy P.; Reddy S.; Lurasidone induced thrombocytopenia: is it a signal of drug induced myelosuppression? Indian J Psychol Med 2018,40(2),191-192","journal-title":"Indian J Psychol Med"},{"key":"ref=26","first-page":"52","volume":"17","author":"Benjamin J.","year":"2018","unstructured":"Benjamin J.; Anand V.; Need hair: pinpointing the cause of a patient\u2019s hair loss. Curr Psychiatr 2018,17(7),52-53","journal-title":"Curr Psychiatr"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"16l02053","DOI":"10.4088\/PCC.16l02053","volume":"19","author":"Tibrewal P","year":"2017","unstructured":"Tibrewal P; Bastiampillai T; Okungu A.; Lurasidone-induced dystonia. Prim care companion CNS Disord 2017,19(3),16l02053","journal-title":"Prim care companion CNS Disord"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16cr11157","volume":"78","author":"Reichenberg J.L.","year":"2017","unstructured":"Reichenberg J.L.; Ridout K.K.; Rickler K.C.; Lurasidone induced rabbit syndrome. J Clin Psychiatry 2017,78(5)","journal-title":"J Clin Psychiatry"},{"key":"ref=29","first-page":"157","volume":"60","author":"Mohanty R.","year":"2018","unstructured":"Mohanty R.; Das B.; Trunkal tardive dyskinesia due to lurasidone-a case report. Indian J Psychiatry 2018,60(5),157-7","journal-title":"Indian J Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2045125316677954","volume":"7","author":"Kanzawa M.","year":"2017","unstructured":"Kanzawa M.; Hadden O.; Case report of a switch to mania induced by lurasidone. Ther Adv Psychopharmacol 2017,7(2),91-93","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/JCP.0000000000000655","volume":"37","author":"Doan L.A.","year":"2017","unstructured":"Doan L.A.; Williams S.R.; Takayesu A.; Lu B.; Case series reports on lurasidone-associated mania. J Clin Psychopharmacol 2017,37(2),264-266","journal-title":"J Clin Psychopharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/JCP.0000000000000774","volume":"37","author":"Lee M.","year":"2017","unstructured":"Lee M.; Marshall D.; Saddichha S.; Lurasidone-associated neuroleptic malignant syndrome. J Clin Psychopharmacol 2017,37(5),639-640","journal-title":"J Clin Psychopharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.9758\/cpn.2017.15.4.413","volume":"15","author":"Sood S.","year":"2017","unstructured":"Sood S.; Neutropenia with multiple antipsychotics including dose dependent neutropenia with lurasidone. Clin Psychopharmacol Neurosci 2017,15(4),413-415","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4088\/PCC.18l02343","volume":"9","author":"Kolli V.","year":"2019","unstructured":"Kolli V.; Walia A.; Kinnan S.; Food matters: reduction of lurasidone-induced nausea with meals. J Neurosci Rural Pract 2019,9(3),446-448","journal-title":"J Neurosci Rural Pract"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4103\/jnrp.jnrp_571_17","volume":"9","author":"Das S.","year":"2018","unstructured":"Das S.; Andi B.S.; Severe extrapyramidal syndrome caused by lurasidone low dose. J Neurosci Rural Pract 2018,9(3),446-448","journal-title":"J Neurosci Rural Pract"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s40278-018-50060-6","volume":"1713","author":"Tripathi R.","year":"2018","unstructured":"Tripathi R.; Lurasidone HCL induced tardive dyskinesia: two cases. Reactions Weekly 2018,1713,226","journal-title":"Reactions Weekly"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4103\/IJPSYM.IJPSYM_266_17","volume":"39","author":"Das S.","year":"2017","unstructured":"Das S.; Agrawal A.; Lurasidone-induced oculogyric crisis. Indian J Psychol Med 2017,39(5),719-720","journal-title":"Indian J Psychol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/IJPSYM.IJPSYM_274_18","volume":"41","author":"Suthar N.","year":"2019","unstructured":"Suthar N.; Aneja J.; Lurasidone-induced Parkinsonism and hyperprolactinemia. Indian J Psychol Med 2019,41(2),192-194","journal-title":"Indian J Psychol Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"18l02370","DOI":"10.4088\/PCC.18l02370","volume":"21","author":"Hafeez ZH","year":"2019","unstructured":"Hafeez ZH; Exanthematous rash with lurasidone in an elderly woman with schizoaffective disorder. Prim Care Companion CNS Disord 2019,21(2),18l02370","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T05:19:26Z","timestamp":1614662366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179895\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200303120147","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}